구조모아 (StructureMoa)항암 chemical structure spider web
방문분석
큐레이션 브리핑
경쟁 포지션: Only FRα-directed ADC approved in ovarian cancer.
기전. Binds FRα, internalizes via receptor-mediated endocytosis, and releases DM4 after disulfide reduction; tubulin disruption causes mitotic arrest, with lipophilic S-methyl-DM4 giving bystander activity.
우선 정리한 핵심 프로그램입니다. 공개 출처가 있는 필드만 표시합니다.
구조화 데이터
FRα (folate receptor alpha)
FRα-positive platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer
US, EU
Approved
elahere · mirvetuximab soravtansine · Elahere · IMGN853 · mirvetuximab-soravtansine-gynx
2026-09-10
Data Confidence · High
Development Signal · Established
Antibody-drug conjugate
DM4 (maytansinoid, tubulin inhibitor)
Cleavable sulfo-SPDB disulfide, DAR ~3.5
Humanized anti-FRα IgG1
FRα is overexpressed in ovarian cancer but sparse in normal tissue, and the label requires IHC-confirmed expression.
구조화 데이터
FRα is overexpressed in ovarian cancer but sparse in normal tissue, and the label requires IHC-confirmed expression.
FRα downregulation and multidrug-resistance transporter upregulation.
DM4 (maytansinoid, tubulin inhibitor)
Cleavable sulfo-SPDB disulfide, DAR ~3.5
DAR 3.5
FRα (folate receptor alpha) · FRα IHC (VENTANA FOLR1 RxDx), PS2+ scoring with ≥75% of tumor cells staining.
Ocular toxicity prophylaxis with steroid and lubricant eye drops
Only FRα-directed ADC approved in ovarian cancer.
FRα-positive platinum-resistant ovarian cancer after 1–3 prior regimens
2L–4L platinum-resistant
IV
6 mg/kg (adjusted ideal body weight) q3w
ORR ~42% in MIRASOL
Ocular toxicity prophylaxis with steroid and lubricant eye drops
Only FRα-directed ADC approved in ovarian cancer.
Binds FRα, internalizes via receptor-mediated endocytosis, and releases DM4 after disulfide reduction; tubulin disruption causes mitotic arrest, with lipophilic S-methyl-DM4 giving bystander activity.
Microtubule destabilization and mitotic catastrophe.
FRα IHC (VENTANA FOLR1 RxDx), PS2+ scoring with ≥75% of tumor cells staining.
FRα downregulation and multidrug-resistance transporter upregulation.
구조화 데이터
ration of response while overcoming T-DXd resistance in patient-derived xenograft
Human, cynomolgus
ADC ~4.8 days
ORR, PFS, OS in FRα-high population
구조화 데이터
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다. 효능 수치는 선택한 등록 결과이며 전적응증 값이 아닙니다.
FDA accelerated approval
APPROVAL · 2022년 11월
FDA full approval on MIRASOL
APPROVAL · 2024년 3월
바이오정보모아는 연구·교육용 과학·의약품 개발 정보입니다. 진료, 진단, 치료 지침, 규제 자문이 아닙니다.
분석
큐레이션 브리핑
경쟁 포지션: Only FRα-directed ADC approved in ovarian cancer.
기전. Binds FRα, internalizes via receptor-mediated endocytosis, and releases DM4 after disulfide reduction; tubulin disruption causes mitotic arrest, with lipophilic S-methyl-DM4 giving bystander activity.
우선 정리한 핵심 프로그램입니다. 공개 출처가 있는 필드만 표시합니다.
구조화 데이터
FRα (folate receptor alpha)
FRα-positive platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer
US, EU
Approved
elahere · mirvetuximab soravtansine · Elahere · IMGN853 · mirvetuximab-soravtansine-gynx
2026-09-10
Data Confidence · High
Development Signal · Established
Antibody-drug conjugate
DM4 (maytansinoid, tubulin inhibitor)
Cleavable sulfo-SPDB disulfide, DAR ~3.5
Humanized anti-FRα IgG1
FRα is overexpressed in ovarian cancer but sparse in normal tissue, and the label requires IHC-confirmed expression.
구조화 데이터
FRα is overexpressed in ovarian cancer but sparse in normal tissue, and the label requires IHC-confirmed expression.
FRα downregulation and multidrug-resistance transporter upregulation.
DM4 (maytansinoid, tubulin inhibitor)
Cleavable sulfo-SPDB disulfide, DAR ~3.5
DAR 3.5
FRα (folate receptor alpha) · FRα IHC (VENTANA FOLR1 RxDx), PS2+ scoring with ≥75% of tumor cells staining.
Ocular toxicity prophylaxis with steroid and lubricant eye drops
Only FRα-directed ADC approved in ovarian cancer.
FRα-positive platinum-resistant ovarian cancer after 1–3 prior regimens
2L–4L platinum-resistant
IV
6 mg/kg (adjusted ideal body weight) q3w
ORR ~42% in MIRASOL
Ocular toxicity prophylaxis with steroid and lubricant eye drops
Only FRα-directed ADC approved in ovarian cancer.
Binds FRα, internalizes via receptor-mediated endocytosis, and releases DM4 after disulfide reduction; tubulin disruption causes mitotic arrest, with lipophilic S-methyl-DM4 giving bystander activity.
Microtubule destabilization and mitotic catastrophe.
FRα IHC (VENTANA FOLR1 RxDx), PS2+ scoring with ≥75% of tumor cells staining.
FRα downregulation and multidrug-resistance transporter upregulation.
구조화 데이터
ration of response while overcoming T-DXd resistance in patient-derived xenograft
Human, cynomolgus
ADC ~4.8 days
ORR, PFS, OS in FRα-high population
구조화 데이터
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다. 효능 수치는 선택한 등록 결과이며 전적응증 값이 아닙니다.
FDA accelerated approval
APPROVAL · 2022년 11월
FDA full approval on MIRASOL
APPROVAL · 2024년 3월
바이오정보모아는 연구·교육용 과학·의약품 개발 정보입니다. 진료, 진단, 치료 지침, 규제 자문이 아닙니다.